Home › Compound Library › Panax Ginseng (Asian Ginseng)

Panax Ginseng (Asian Ginseng)

Herboral · inferred

Standardized Asian ginseng (Panax ginseng) or American ginseng (Panax quinquefolius), typically 4-7% ginsenosides. Adaptogenic herb with blood-glucose-lowering effects.

Projected serum levels — 400 mg, once daily

Panax Ginseng (Asian Ginseng)
Panax Ginseng (Asian Ginseng) modeled serum levels, 400 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 3 days. 0 12.5 25 37.5 50 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 3
Panax Ginseng (Asian Ginseng) modeled serum levels with a loading dose of 801 mg, then 400 mg once daily The first dose is larger so levels approach steady state faster. 0 12.5 25 37.5 50 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 400 mg once daily (oral).

Loading schedule: 801 mg on day 1, then 400 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~3 days: peak ≈ 33.6 mg, trough ≈ 19.8 mg body load. Population-based estimate over 15 days for a 400 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Herb
Route modeled
Oral
Model confidence
inferred
Half-life
24 h
Common dose
400 mg
Suggested maximum
2k mg/day
Reference dose range
200–2k mg (single dose)
Suggested cadence
once daily

Documented interactions

  • danger
    4-MMC (Mephedrone) + Panax Ginseng (Asian Ginseng) CYP inhibition

    Panax Ginseng (Asian Ginseng) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) + Panax Ginseng (Asian Ginseng) CYP inhibition

    Panax Ginseng (Asian Ginseng) reversible_inhibitor of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~3.33x

  • danger
    Amphetamine (Adderall) + Panax Ginseng (Asian Ginseng) CYP inhibition

    Panax Ginseng (Asian Ginseng) reversible_inhibitor of CYP2D6 predicted to change Amphetamine (Adderall) AUC by ~2.11x

  • danger
    Atomoxetine (Strattera) + Panax Ginseng (Asian Ginseng) CYP inhibition

    Panax Ginseng (Asian Ginseng) reversible_inhibitor of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~2.68x

  • danger
    Dextromethorphan (DXM) + Panax Ginseng (Asian Ginseng) CYP inhibition

    Panax Ginseng (Asian Ginseng) reversible_inhibitor of CYP2D6 predicted to change Dextromethorphan (DXM) AUC by ~2.47x

  • danger
    DOM (2,5-Dimethoxy-4-methylamphetamine / STP) + Panax Ginseng (Asian Ginseng) CYP inhibition

    Panax Ginseng (Asian Ginseng) reversible_inhibitor of CYP2D6 predicted to change DOM (2,5-Dimethoxy-4-methylamphetamine / STP) AUC by ~3.33x

Serum checks 356 modeled interaction pairings for panax ginseng (asian ginseng) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Therapeutic potential of ginsenosides on diabetes: From hypoglycemic mechanism to clinical trials Jung SH et al. · Journal of Functional Foods, 2019 DOI

    Ginsenosides mechanisms and clinical RCT evidence.

  2. The Effect of Ginseng (The Genus Panax) on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials Vaya J et al. · PLOS One, 2014 DOI

    Meta-analysis of 16 RCTs showing glucose reduction.

  3. Influence of Panax ginseng on Cytochrome P450 (CYP)3A and P-glycoprotein (Pgp) Activity in Healthy Subjects Malati CY et al. · Journal of Clinical Pharmacy and Therapeutics, 2012 DOI

    CYP3A4 induction study.

  4. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, Penzak SR · Journal of clinical pharmacology, 2012 DOI

    This citation reports a human clinical study involving Panax Ginseng (Asian Ginseng). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

4 published studies referenced in the app, each with a plain-language summary.